Fadi Layous, MD
Pulmonary Disease · Munster, INNPI 1912955584
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 57 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 54.2% of the total. Reporting peaked in 2021 at $24,102 and has fallen 86.4% since, to $3,275 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 788 payments — averaging $81.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$35K
- Mylan Specialty L.p.$10K
- Intuitive Surgical$2K
- Johnson & Johnson$2K
- AstraZeneca$2K
- GSK$1K
- plus $12K from 51 others
What the payments were for
- Consulting fees$2,0403%
- Speaking & faculty fees$37,73659%
- Travel & lodging$4,1216%
- Food & beverage$18,05628%
- Education$1,9393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$33,285
- Yupelri$8,821
- Da Vinci Surgical System$2,320
- Monarch Platform$1,434
- superDimension$893
- Inspire Upper Airway Stimulation System$721
- ACQUIRE$292
- WatchPATONE$237
- MONARCH$190
- remede System$176
- ALIYA SYSTEM$138
- SPYGLASS$123
- ZEPOSIA$117
- Inspire$116
- DUPIXENT$114
- Adempas$110
How this compares
$63,892 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 64 | $876,905 |
| OfevNintedanib Esylate | 60 | $777,837 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 598 | $648,543 |
| TezspireTezepelumab-Ekko | 68 | $274,860 |
| XolairOmalizumab | 45 | $149,138 |
| Breo ElliptaFluticasone/Vilanterol | 185 | $135,089 |
| Spiriva RespimatTiotropium Bromide | 128 | $127,397 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $86,123 |
| Ambrisentan | 28 | $83,656 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $63,957 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $59,914 |
| Dupixent SyringeDupilumab | 13 | $48,221 |
| EliquisApixaban | 31 | $21,015 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $17,541 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 512 | $14,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $478 | $972,367289 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,486 | $895,398932 claims |
| BayerAdempas | $505 | $876,90564 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,937 | $351,619178 claims |
| PfizerEliquis | $57 | $21,01531 claims |
| MerckDulera | $180 | $11,26119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Munster
- Asaad JandaliMunster$161K
- Bassem SrourMunster$16K
- Wassim ShwaikiMunster$16K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.